ENTRADA THERAPEUTICS, INC. Operating Income
ENTRADA THERAPEUTICS, INC. (TRDA) reported Operating Income of -$44.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$44.96M.
- ENTRADA THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$42.30M.
- ENTRADA THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$42.21M.
- ENTRADA THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$47.05M.
- ENTRADA THERAPEUTICS, INC. operating income (loss) for fiscal 2025 was -$157.90M, a 435.87% decline from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. operating income (loss) for fiscal 2024 was $47.01M.
- ENTRADA THERAPEUTICS, INC. operating income (loss) for fiscal 2023 was -$3.16M.
- ENTRADA THERAPEUTICS, INC. operating income (loss) for fiscal 2022 was -$97.25M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$44.96M 10-Q · filed 2026-08-05 | -$87.27M 10-Q · filed 2026-08-05 | -$129.47M derived: sum of 3 quarters · filed 2026-08-05 | -$176.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$42.30M 10-Q · filed 2026-05-07 | -$84.51M derived: sum of 2 quarters · filed 2026-05-07 | -$131.56M derived: sum of 3 quarters · filed 2026-05-07 | -$178.41M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$42.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$89.26M derived: sum of 2 quarters · filed 2026-02-26 | -$136.11M derived: sum of 3 quarters · filed 2026-08-05 | -$157.90M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$47.05M 10-Q · filed 2025-11-06 | -$93.90M derived: sum of 2 quarters · filed 2026-08-05 | -$115.69M 10-Q · filed 2025-11-06 | -$121.56M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$46.85M 10-Q · filed 2026-08-05 | -$68.64M 10-Q · filed 2026-08-05 | -$74.51M derived: sum of 3 quarters · filed 2026-08-05 | -$96.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$21.79M 10-Q · filed 2026-05-07 | -$27.66M derived: sum of 2 quarters · filed 2026-05-07 | -$49.31M derived: sum of 3 quarters · filed 2026-05-07 | $4.11M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$5.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$27.52M derived: sum of 2 quarters · filed 2026-02-26 | $25.90M derived: sum of 3 quarters · filed 2026-02-26 | $47.01M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$21.66M 10-Q · filed 2025-11-06 | $31.77M derived: sum of 2 quarters · filed 2025-11-06 | $52.88M 10-Q · filed 2025-11-06 | $57.78M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $53.42M 10-Q · filed 2025-08-06 | $74.54M 10-Q · filed 2025-08-06 | $79.44M derived: sum of 3 quarters · filed 2025-08-06 | $93.45M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $21.11M 10-Q · filed 2025-05-08 | $26.02M derived: sum of 2 quarters · filed 2025-05-08 | $40.03M derived: sum of 3 quarters · filed 2025-05-08 | $23.73M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $4.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $18.92M derived: sum of 2 quarters · filed 2025-02-27 | $2.62M derived: sum of 3 quarters · filed 2025-02-27 | -$3.16M 10-K · filed 2025-02-27 |
| 2023-09-30 | $14.01M 10-Q · filed 2024-11-05 | -$2.29M derived: sum of 2 quarters · filed 2024-11-05 | -$8.07M 10-Q · filed 2024-11-05 | -$33.65M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$16.30M 10-Q · filed 2024-08-13 | -$22.08M 10-Q · filed 2024-08-13 | -$47.66M derived: sum of 3 quarters · filed 2024-08-13 | -$73.59M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$5.78M 10-Q · filed 2024-05-07 | -$31.36M derived: sum of 2 quarters · filed 2024-05-07 | -$57.30M derived: sum of 3 quarters · filed 2024-05-07 | -$80.88M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$25.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$51.52M derived: sum of 2 quarters · filed 2024-03-13 | -$75.10M derived: sum of 3 quarters · filed 2024-03-13 | -$97.25M 10-K · filed 2024-03-13 |
| 2022-09-30 | -$25.94M 10-Q · filed 2023-11-07 | -$49.52M derived: sum of 2 quarters · filed 2023-11-07 | -$71.67M 10-Q · filed 2023-11-07 | -$90.13M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$23.58M 10-Q · filed 2023-08-08 | -$45.73M 10-Q · filed 2023-08-08 | -$64.19M derived: sum of 3 quarters · filed 2023-08-08 | -$78.56M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$22.15M 10-Q · filed 2023-05-10 | -$40.61M derived: sum of 2 quarters · filed 2023-05-10 | -$54.98M derived: sum of 3 quarters · filed 2023-05-10 | -$64.89M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$18.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$32.82M derived: sum of 2 quarters · filed 2023-03-06 | -$42.73M derived: sum of 3 quarters · filed 2023-03-06 | -$51.13M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$14.36M 10-Q · filed 2022-11-07 | -$24.27M derived: sum of 2 quarters · filed 2022-11-07 | -$32.67M 10-Q · filed 2022-11-07 | -$41.32M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$9.91M 10-Q · filed 2022-08-11 | -$18.30M 10-Q · filed 2022-08-11 | -$26.96M derived: sum of 3 quarters · filed 2022-08-11 | -$33.93M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$8.39M 10-Q · filed 2022-05-12 | -$17.05M derived: sum of 2 quarters · filed 2022-05-12 | -$24.02M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$8.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$15.63M derived: sum of 2 quarters · filed 2022-03-15 | -$26.67M 10-K · filed 2022-03-15 | |
| 2020-09-30 | -$6.97M 10-Q · filed 2021-12-09 | -$18.01M 10-Q · filed 2021-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |